In the case of type 1 diabetes, the rationale for administering TNF is that insulin-autoreactive T cells bear several intracellular signaling defects that make them selectively vulnerable to death upon exposure to TNF [4]–[7]. The gene discussed is TNF; the disease is type 1 diabetes mellitus.